Prostate Cancer – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Prostate Cancer – Pipeline Review, H2 2020’, provides an overview of the Prostate Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Prostate Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Prostate Cancer

– The report reviews pipeline therapeutics for Prostate Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Prostate Cancer therapeutics and enlists all their major and minor projects

– The report assesses Prostate Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Prostate Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Prostate Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Prostate Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4D Pharma Plc

4SC AG

Aavocyte Inc

AB Science SA

Abbisko Therapeutics Co Ltd

AbbVie Inc

Abion Inc

Actinium Pharmaceuticals Inc

Adicet Bio Inc

Advanced Accelerator Applications SA

Advaxis Inc

Adze Biotechnology Inc

Aeglea BioTherapeutics Inc

Affina Biotechnologies Inc

Agenus Inc

AIkido Pharma Inc

AIM ImmunoTech Inc

Akshaya Bio Inc

Alla Chem LLC

Allarity Therapeutics A/S

Allife Medical Science and Technology Co Ltd

Alligator Bioscience AB

Almac Discovery Ltd

AlphaMab Co Ltd

Alphamab Oncology

ALRISE Biosystems GmbH

Altay Therapeutics Inc

Ambrx Inc

American Gene Technologies International Inc

Amgen Inc

Anastasis Biotec Ltd

Anavex Life Sciences Corp

Andes Biotechnologies

Anew Oncology Inc

AnGes Inc

Antapodia Therapeutics Inc

AntiCancer Inc

Antikor Biopharma Ltd

Apcure SAS

Apexian Pharmaceuticals Inc

Aphios Corp

Apidel SA

APIM Therapeutics AS

Aprilbio Co Ltd

Aqualung Therapeutics Corp

Aranda Pharma Ltd

Arch Oncology Inc

Arcus Biosciences Inc

Ariz Precision Medicine Inc

Arrien Pharmaceuticals LLC

Artelo Biosciences Inc

Arvinas Inc

Ascelia Pharma AB

Asdera LLC

Asieris Pharmaceuticals Co Ltd

AskAt Inc

AstraZeneca Plc

Athenex Inc

AUM Biosciences Pte Ltd

Auransa Inc

Aurigene Discovery Technologies Ltd

Autolus Therapeutics Plc

Avican Inc

Avivia BV

B3 Bio Inc

Bantam Pharmaceutical LLC

Basilea Pharmaceutica Ltd

Bavarian Nordic A/S

Bayer AG

BeiGene Ltd

Beijing Konruns Pharmaceutical Co Ltd

Bellicum Pharmaceuticals Inc

Better Life Pharmaceuticals Inc

Bexion Pharmaceuticals LLC

BeyondSpring Inc

Bicycle Therapeutics Plc

Bio-Cancer Treatment International Ltd

BioAtla LLC

BioCurity Pharmaceuticals Inc

BioEclipse Therapeutics Inc

Biokine Therapeutics Ltd

BioNTech SE

Biopep Solutions Inc

Biosceptre International Ltd

Biosion Inc

BioVec Pharma Inc

Bioven Group

BioXcel Therapeutics Inc

bluebird bio Inc

Boehringer Ingelheim International GmbH

BriaCell Therapeutics Corp

Bristol-Myers Squibb Co

Bukwang Pharmaceutical Co Ltd

Calidi Biotherapeutics Inc

Calidum Inc

Camurus AB

Can-Fite BioPharma Ltd

CanBas Co Ltd

Cancer Targeted Technology LLC

Candel Therapeutics

Canget BioTekpharma LLC

Cardiff Oncology Inc

Carrick Therapeutics UK Ltd

CAS-Lamvac Biotech Co Ltd

Cassiopea SpA

Cellbion Co Ltd

CellCentric Ltd

Celldex Therapeutics Inc

Cellestia Biotech AG

Cellid Co Ltd

Cellmid Ltd

Cello Therapeutics Inc

Cells for Cells SA

Celprogen Inc

Celtek Bioscience LLC

ChemRegen Inc

Chong Kun Dang Pharmaceutical Corp

Clarity Pharmaceuticals Pty Ltd

Cloaked Therapeutics LLC

Clovis Oncology Inc

CMG Pharmaceutical Co Ltd

Table of Contents

Table of Contents

Introduction

Prostate Cancer - Overview

Prostate Cancer - Therapeutics Development

Prostate Cancer - Therapeutics Assessment

Prostate Cancer - Companies Involved in Therapeutics Development

Prostate Cancer - Drug Profiles

Prostate Cancer - Dormant Projects

Prostate Cancer - Discontinued Products

Prostate Cancer - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Prostate Cancer, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Prostate Cancer – Pipeline by 4D Pharma Plc, H2 2020

Prostate Cancer – Pipeline by 4SC AG, H2 2020

Prostate Cancer – Pipeline by Aavocyte Inc, H2 2020

Prostate Cancer – Pipeline by AB Science SA, H2 2020

Prostate Cancer – Pipeline by Abbisko Therapeutics Co Ltd, H2 2020

Prostate Cancer – Pipeline by AbbVie Inc, H2 2020

Prostate Cancer – Pipeline by Abion Inc, H2 2020

Prostate Cancer – Pipeline by Actinium Pharmaceuticals Inc, H2 2020

Prostate Cancer – Pipeline by Adicet Bio Inc, H2 2020

Prostate Cancer – Pipeline by Advanced Accelerator Applications SA, H2 2020

Prostate Cancer – Pipeline by Advaxis Inc, H2 2020

Prostate Cancer – Pipeline by Adze Biotechnology Inc, H2 2020

Prostate Cancer – Pipeline by Aeglea BioTherapeutics Inc, H2 2020

Prostate Cancer – Pipeline by Affina Biotechnologies Inc, H2 2020

Prostate Cancer – Pipeline by Agenus Inc, H2 2020

Prostate Cancer – Pipeline by AIkido Pharma Inc, H2 2020

Prostate Cancer – Pipeline by AIM ImmunoTech Inc, H2 2020

Prostate Cancer – Pipeline by Akshaya Bio Inc, H2 2020

Prostate Cancer – Pipeline by Alla Chem LLC, H2 2020

Prostate Cancer – Pipeline by Allarity Therapeutics A/S, H2 2020

Prostate Cancer – Pipeline by Allife Medical Science and Technology Co Ltd, H2 2020

Prostate Cancer – Pipeline by Alligator Bioscience AB, H2 2020

Prostate Cancer – Pipeline by Almac Discovery Ltd, H2 2020

Prostate Cancer – Pipeline by AlphaMab Co Ltd, H2 2020

Prostate Cancer – Pipeline by Alphamab Oncology, H2 2020

Prostate Cancer – Pipeline by ALRISE Biosystems GmbH, H2 2020

Prostate Cancer – Pipeline by Altay Therapeutics Inc, H2 2020

Prostate Cancer – Pipeline by Ambrx Inc, H2 2020

Prostate Cancer – Pipeline by American Gene Technologies International Inc, H2 2020

Prostate Cancer – Pipeline by Amgen Inc, H2 2020

Prostate Cancer – Pipeline by Anastasis Biotec Ltd, H2 2020

Prostate Cancer – Pipeline by Anavex Life Sciences Corp, H2 2020

Prostate Cancer – Pipeline by Andes Biotechnologies, H2 2020

Prostate Cancer – Pipeline by Anew Oncology Inc, H2 2020

Prostate Cancer – Pipeline by AnGes Inc, H2 2020

Prostate Cancer – Pipeline by Antapodia Therapeutics Inc, H2 2020

Prostate Cancer – Pipeline by AntiCancer Inc, H2 2020

Prostate Cancer – Pipeline by Antikor Biopharma Ltd, H2 2020

Prostate Cancer – Pipeline by Apcure SAS, H2 2020

Prostate Cancer – Pipeline by Apexian Pharmaceuticals Inc, H2 2020

Prostate Cancer – Pipeline by Aphios Corp, H2 2020

Prostate Cancer – Pipeline by Apidel SA, H2 2020

Prostate Cancer – Pipeline by APIM Therapeutics AS, H2 2020

Prostate Cancer – Pipeline by Aprilbio Co Ltd, H2 2020

Prostate Cancer – Pipeline by Aqualung Therapeutics Corp, H2 2020

Prostate Cancer – Pipeline by Aranda Pharma Ltd, H2 2020

Prostate Cancer – Pipeline by Arch Oncology Inc, H2 2020

Prostate Cancer – Pipeline by Arcus Biosciences Inc, H2 2020

Prostate Cancer – Pipeline by Ariz Precision Medicine Inc, H2 2020

Prostate Cancer – Pipeline by Arrien Pharmaceuticals LLC, H2 2020

Prostate Cancer – Pipeline by Artelo Biosciences Inc, H2 2020

Prostate Cancer – Pipeline by Arvinas Inc, H2 2020

Prostate Cancer – Pipeline by Ascelia Pharma AB, H2 2020

Prostate Cancer – Pipeline by Asdera LLC, H2 2020

Prostate Cancer – Pipeline by Asieris Pharmaceuticals Co Ltd, H2 2020

Prostate Cancer – Pipeline by AskAt Inc, H2 2020

Prostate Cancer – Pipeline by AstraZeneca Plc, H2 2020

Prostate Cancer – Pipeline by Athenex Inc, H2 2020

Prostate Cancer – Pipeline by AUM Biosciences Pte Ltd, H2 2020

Prostate Cancer – Pipeline by Auransa Inc, H2 2020

Prostate Cancer – Pipeline by Aurigene Discovery Technologies Ltd, H2 2020

Prostate Cancer – Pipeline by Autolus Therapeutics Plc, H2 2020

Prostate Cancer – Pipeline by Avican Inc, H2 2020

Prostate Cancer – Pipeline by Avivia BV, H2 2020

Prostate Cancer – Pipeline by B3 Bio Inc, H2 2020

Prostate Cancer – Pipeline by Bantam Pharmaceutical LLC, H2 2020

Prostate Cancer – Pipeline by Basilea Pharmaceutica Ltd, H2 2020

Prostate Cancer – Pipeline by Bavarian Nordic A/S, H2 2020

Prostate Cancer – Pipeline by Bayer AG, H2 2020

Prostate Cancer – Pipeline by BeiGene Ltd, H2 2020

Prostate Cancer – Pipeline by Beijing Konruns Pharmaceutical Co Ltd, H2 2020

Prostate Cancer – Pipeline by Bellicum Pharmaceuticals Inc, H2 2020

Prostate Cancer – Pipeline by Better Life Pharmaceuticals Inc, H2 2020

Prostate Cancer – Pipeline by Momotaro-Gene Inc, H2 2020

Prostate Cancer – Pipeline by Multitude therapeutics Inc, H2 2020

Prostate Cancer – Pipeline by Mustang Bio Inc, H2 2020

List of Figures

List of Figures

Number of Products under Development for Prostate Cancer, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports